Amphetamine, as well as other psychostimulants such as cocaine and methylphenidate, has a high potential for abuse. The primary mechanism of action of these drugs is the inhibition of the dopamine plasma membrane transporter (DAT) which results in elevated levels of dopamine at the synapse. These drugs can cause long lasting synaptic changes upon repeated exposure that may be important for their subsequent addictive properties. We are interested in characterizing the mechanisms that contribute to amphetamine modulation of dopaminergic pathways.Administration of amphetamine to wild-type animals results in a dose dependent inhibition of locomotion, egg laying, and pharyngeal pumping. These behavioral effects are similar to those produced by exposing animals to exogenous dopamine, suggesting that amphetamine may act on dopaminergic pathways in C. elegans. We completed a genetic screen of 5200 genomes to identify mutants resistant to the effects of amphetamine on locomotion and identified eight candidates. We then characterized the mutants for defects in a specific dopamine-mediated behavior previously described by Sawin et al (Neuron 26: 619-31, 2000). Sawin demonstrated that mutants defective in the synthesis of dopamine fail to slow upon re-entry onto a bacterial lawn. Four of the amphetamine resistant mutants show an absence of slowing or reduced slowing in this assay. None of the mutants showed other obvious phenotypes. To distinguish between possible pre- and postsynaptic defects at dopaminergic synapses, we tested these mutants for resistance to exogenous dopamine. All of these mutants proved sensitive to exogenous dopamine suggesting presynaptic defects or abnormalities upstream of the dopaminergic synapses. In order to find mutants resistant to the effects psychostimulants due to postsynaptic defects, we initiated a genetic screen for animals resistant to the inhibitory effect of exogenous dopamine on thrashing in liquid. In a screen of 2500 genomes, we identified three mutants (
eg643,
eg644 and
eg645) resistant to the effects of exogenous dopamine. Additional pharmacological experiments revealed altered sensitivity of some of these mutants to additional compounds that act at dopamine receptors in other systems including quinperole (a D2 agonist) and raclopride (a D2 antagonist). Two of the mutants (
eg643 and
eg645) also exhibited reduced sensitivity to amphetamine. In behavioral assays,
eg644 fails to slow upon re-entering a bacterial lawn. We are currently in the process of mapping and cloning the genes responsible for these mutant phenotypes.